Sugi Predict

Sugi Predict / Compounds / SCHEMBL9998673

SCHEMBL9998673

SCHEMBL9998673

CCCOc1ncccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 7/20 0.36
▸ LIPG Q9Y5X9 7/20 0.36
▸ LIPE Q05469 4/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ ROCK2 O75116 1/20 0.34
▸ PDE1A P54750 1/20 0.32
▸ PDE1B Q01064 1/20 0.32
▸ PDE1C Q14123 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ GRM5 P41594 1/20 0.32
▸ DGAT1 O75907 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30138169 1.00 LPL (0.36) LPLLIPGLIPENPC1HPGD
SCHEMBL365301 0.88 L3MBTL1 (0.36) LPLLIPGLIPENPC1HPGD
SCHEMBL29900384 0.88 L3MBTL1 (0.36) LPLLIPGLIPENPC1HPGD
SCHEMBL20581129 0.85 CHRNB2 (0.41) LIPEMAPTPOLB
SCHEMBL30292561 0.81 APLNR (0.38) LPLLIPGLIPENPC1RAB9A
SCHEMBL1484864 0.81 APLNR (0.38) LPLLIPGLIPENPC1RAB9A
Water SCHEMBL2513501 0.80 APLNR (0.37) LPLLIPGLIPENPC1RAB9A
SCHEMBL25300352 0.80 LIPE (0.42) LIPE
SCHEMBL20428054 0.80 LIPE (0.35) LPLLIPGLIPEROCK2DGAT1
SCHEMBL29879749 0.80 LIPE (0.42) LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851425-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines H. LUNDBECK A/S (DK) 2023-12-26 — — US disclosed
CN-111556871-B 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors H.隆德贝克有限公司 2023-07-07 — — CN disclosed
US-11634416-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines H. LUNDBECK A/S (DK) 2023-04-25 — — US disclosed
CN-110099901-B Pyrazolo [3,4-b ] pyridines and imidazo [1,5-b ] pyridazines as PDE1 inhibitors H.隆德贝克有限公司 2023-01-03 — — CN disclosed
US-11491140-B2 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors H. LUNDBECK A/S (DK) 2022-11-08 — — US disclosed
CN-111526890-B Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine H.隆德贝克有限公司 2022-10-14 — — CN disclosed
EP-3723808-B1 COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES H LUNDBECK AS (DK) 2021-10-20 — — EP disclosed
EP-3723807-B1 COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES H LUNDBECK AS (DK) 2021-10-20 — — EP disclosed
CN-109311872-B 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors H.隆德贝克有限公司 2021-08-20 — — CN disclosed
EP-3558988-B1 PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS H LUNDBECK AS (DK) 2021-07-07 — — EP disclosed
WO-2018115067-A1 PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS H. LUNDBECK A/S (DK) 2018-06-28 — — WO disclosed
US-20180179200-A1 PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS H. LUNDBECK A/S (DK) 2018-06-28 — — US disclosed
US-20180179200-A1 PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS H. LUNDBECK A/S (DK) 2018-06-28 — — US disclosed
WO-2018115067-A1 PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS H. LUNDBECK A/S (DK) 2018-06-28 — — WO disclosed
US-20180179200-A1 PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS H. LUNDBECK A/S (DK) 2018-06-28 — — US disclosed
WO-2018007249-A1 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS H. LUNDBECK A/S (DK) 2018-01-11 — — WO disclosed
US-20180000786-A1 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors H. LUNDBECK A/S (DK) 2018-01-04 — — US disclosed
WO-2016055947-A1 ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2016-04-14 — — WO disclosed
WO-2013093688-A1 SULFONAMIDE DERIVATIVES AND USE THEREOF AS VGSC INHIBITORS PFIZER LIMITED (GB) 2013-06-27 — — WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11851425-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines PDE3B, PDE1B, PDE12 LPL 3114/4885LIPG 4327/4885LIPE 4139/4885
US-11491140-B2 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors PDE3A, PDE5A, PDE12 LPL 2346/4885LIPG 3666/4885LIPE 3654/4885
US-11634416-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines PDE1B, PDE3B, PDE1A LPL 3316/4885LIPG 4670/4885LIPE 3947/4885
US-20180000786-A1 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors PDE3A, PDE5A, PDE12 LPL 2351/4885LIPG 3656/4885LIPE 3637/4885
US-20180179200-A1 PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS PDE5A, PDE12, PDE3A LPL 2448/4885LIPG 4082/4885LIPE 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.